Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Si

Showing results (91-100 of 230) with videos related to

Pageof 23
Sort By:
BMC Cancer|May 28, 2021
Genetic alteration of Chinese patients with rectal mucosal melanomaHuan Li, Lujing Yang, Yumei Lai, et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|February 11, 2014
[Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas]Zhong-wu Li, Yan Wang, Wei-cheng Xue, et al.
Frontiers in Immunology|July 18, 2022
<i>CCND1</i> Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor MicroenvironmentJun Liu, Jing Lin, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II StudyLili Mao, Meiyu Fang, Yu Chen, et al.
BMC Cancer|November 11, 2024
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective studyXiaojun Cai, Jing Lin, Caili Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway InhibitorsYan Kong, Lu Si, Yiqian Li, et al.
Annals of Surgical Oncology|December 23, 2017
Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in ChinaSiming Li, Xinan Sheng, Lu Si, et al.
International Immunopharmacology|January 8, 2026
Corrigendum to "Obacunone inhibits RIPK1/RIPK3/MLKL-mediated necroptosis by suppressing mitochondrial ROS and MIF signaling in intestinal ischemia-reperfusion injury" [Int. Immunopharmacol. 168 (2026) 115901]Xiao-Yao Li, Jing-Yuan Xie, Yu-Tong Yin, et al.
International Immunopharmacology|November 29, 2025
Obacunone inhibits RIPK1/RIPK3/MLKL-mediated necroptosis by suppressing mitochondrial ROS and MIF signaling in intestinal ischemia-reperfusion injuryXiao-Yao Li, Jing-Yuan Xie, Yu-Tong Yin, et al.
Journal of Cancer|July 27, 2023
Prognostic Value of Lymph Node Necrosis at Different N Stages in Patients with Nasopharyngeal CarcinomaYue-Chun Fu, Shao-Bo Liang, Wen-Jie Huang, et al.
Pageof 23

Showing results (91-100 of 230) with videos related to

Sort By:
Pageof 23
BMC Cancer|May 28, 2021
Genetic alteration of Chinese patients with rectal mucosal melanomaHuan Li, Lujing Yang, Yumei Lai, et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|February 11, 2014
[Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas]Zhong-wu Li, Yan Wang, Wei-cheng Xue, et al.
Frontiers in Immunology|July 18, 2022
<i>CCND1</i> Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor MicroenvironmentJun Liu, Jing Lin, Xuefeng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II StudyLili Mao, Meiyu Fang, Yu Chen, et al.
BMC Cancer|November 11, 2024
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective studyXiaojun Cai, Jing Lin, Caili Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway InhibitorsYan Kong, Lu Si, Yiqian Li, et al.
Annals of Surgical Oncology|December 23, 2017
Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in ChinaSiming Li, Xinan Sheng, Lu Si, et al.
International Immunopharmacology|January 8, 2026
Corrigendum to "Obacunone inhibits RIPK1/RIPK3/MLKL-mediated necroptosis by suppressing mitochondrial ROS and MIF signaling in intestinal ischemia-reperfusion injury" [Int. Immunopharmacol. 168 (2026) 115901]Xiao-Yao Li, Jing-Yuan Xie, Yu-Tong Yin, et al.
International Immunopharmacology|November 29, 2025
Obacunone inhibits RIPK1/RIPK3/MLKL-mediated necroptosis by suppressing mitochondrial ROS and MIF signaling in intestinal ischemia-reperfusion injuryXiao-Yao Li, Jing-Yuan Xie, Yu-Tong Yin, et al.
Journal of Cancer|July 27, 2023
Prognostic Value of Lymph Node Necrosis at Different N Stages in Patients with Nasopharyngeal CarcinomaYue-Chun Fu, Shao-Bo Liang, Wen-Jie Huang, et al.
Pageof 23